Fresh analysis indicates that people who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle programs.
Findings released in a leading health publication points out that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be cognizant of the danger of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about 18 months.
Comparing Treatments
The analysis, which reviewed dozens of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
Scientists point out that people who lose weight through lifestyle changes alone generally see a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Doctors believe the mechanism of the injections explains the amplified rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating a significant risk."
An Ongoing Issue?
Health authorities advise the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who state that the findings "emphasize the persistent nature of excess weight," akin to managing conditions like high blood pressure.
Patient Experiences
Individuals who have stopped the jabs report a sudden return of appetite.
"It felt as if a switch flipping and you're instantly extremely hungry," described an individual.
The struggle is exacerbated if users have not established sustainable dietary or behavioural modifications during treatment.
Significant Adoption
Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is higher among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are effective tools for weight loss, they are not a permanent cure and long-term success hinges on ongoing lifestyle management.
